News | August 02, 2022
Cadila launches generic sitagliptin versions to treat uncontrolled type 2 diabetes
The two generic drugs have been launched under the brand names Jankey & Sitenali.
The two generic drugs have been launched under the brand names Jankey & Sitenali.
he company has reported total income of Rs. 5478.62 crores during the period ended June 30, 2022.
The Award reinforces Cadila’s digital initiatives which is backed by innovation, research & development and robust frameworks.
Dr. Mona frequently treats children experiencing localized reactions from insect bites and stings.
The partnership will accelerate stockpiling, channel distribution and hospital access for the amubarvimab/romlusevimab combination in China
Upgrades and global expansion provide additional control, visibility, reliability and recovery for patient-critical, time-and temperature-sensitive products
This acquisition is in line with Cipla's strategic imperative to augment the company's wellness portfolio for bringing about a shift from an illness to a wellness mindset.
Philips demonstrates portfolio of smart connected imaging systems and integrated radiology workflow solutions designed to improve diagnostic confidence and clinical outcomes
Supports development and commercialization of complex oral drugs using sensitive molecules, including biologicals
These medicines have low risk of hypoglycemia, provide beta cell protection, offer cardio-renal benefits and are safe for patients with kidney or liver conditions and senior citizens
Subscribe To Our Newsletter & Stay Updated
